Search - tctmd.com

Displaying 21 - 40 of 285

Sort: Relevancy | Date

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2020

Shelley Wood

October 30, 2020

News Conference News TCT 2020

OPTIMIZE: Svelte Direct Stenting Device Fails to Match DES

L.A. McKeown

October 17, 2020

Presentation TCT 2020

The PROSPECT ABSORB Trial: Randomized Evaluation of Vulnerable Plaque Treatment with Percutaneous Coronary Intervention

Presenter: Gregg Stone

October 14, 2020

News Conference News TCT 2020

Prophylactic PCI of Vulnerable Plaques? PROSPECT II/ABSORB

Michael O'Riordan

October 14, 2020

News Conference News CRT 2020

Newer, Thinner-Strut Abbott Scaffold Prompts Talk of a BVS Comeback

Michael O'Riordan

February 28, 2020

News Daily News

Clopidogrel Interaction With Morphine in ACS Linked to More Ischemic Events

Shelley Wood

January 20, 2020

News Conference News TCT 2019

Ultrathin-Strut Orsiro Stent as Good as BioMatrix: BIODEGRADE

Michael O'Riordan

September 30, 2019

Presentation TCT Abstracts Posters 2019

Impact of Calcified Plaque Angulation on Clinical Outcomes Following Bioresorbable Vascular Scaffold Implantation: Insights from ABSORB III and ABSORB Japan

Presenter: Shinji Imura

September 29, 2019

Presentation TCT 2019

The Post-Absorb BVS Era: Lessons Learned and Implications for Trial Design and Device Approval

Presenter: Andrew Farb

September 28, 2019

Presentation TCT 2019

The Absorb BVS Epilogue: How Did We Miss the Safety Signals?

Presenter: Renu Virmani

September 28, 2019

Presentation TCT 2019

TCT 7: Blinded Outcomes Assessment of Absorb Bioresorbable Scaffolds Implanted With Improved Technique: Two-year Results From the ABSORB IV Randomized Trial

Presenter: Gregg Stone

September 28, 2019

Presentation TCT 2019

ABSORB 5-Year Pooled Analysis: Improving Very Late Outcomes of the Absorb Bioresorbable Scaffold in Coronary Artery Disease From 4 Randomized Trials

Presenter: Gregg Stone

September 27, 2019

Presentation TCT 2019

Detection of Vulnerable Patients by NIRS (PROSPECT II) and Treatment (PROSPECT ABSORB) Rationale and Update

Presenter: David Erlinge

September 27, 2019

Presentation TCT 2019

TCT 48: Bioresorbable Scaffold Versus Metallic Drug-Eluting Stent in Patients at High Risk of Restenosis (COMPARE-ABSORB trial) : Very late device thrombosis while on extended DAPT

Presenter: Robert-Jan Van Geuns

September 25, 2019

Presentation TCT 2019

TCT 47: Five-Year Clinical Outcomes From Randomized Comparison of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents in Patients With Coronary Artery Disease From ABSORB China Trial

Presenter: Run-Lin Gao

September 25, 2019

Presentation TCT 2019

TCT 11: Everolimus-eluting Bioresorbable Scaffolds versus Drug-eluting Stents in Patients with Acute Myocardial Infarction – 2-Year Results of the Randomized ISAR-Absorb MI Trial

Presenter: Jens Wiebe

September 25, 2019

News Industry News

SINOMED® Concludes Enrollment of the PIONEER III Randomized, Pivotal Study of the BuMA Supreme® Coronary Drug-Eluting Stent

July 23, 2019

News Conference News EuroPCR 2019

Cardiogenic Shock Old and New: IABPs a Thing of the Past and ECMO Under Study

Caitlin E. Cox

June 05, 2019

News Conference News EuroPCR 2019

Daring to Dream: New BRS Data Hint at Low MACE Rates at 2 and 3 Years

Michael O'Riordan

May 27, 2019

Presentation

Myocardial Blood Flow and Coronary Flow Reserve 3 Years After Absorb BVS vs DES: VANISH

April 30, 2019

Advertisement

TCTMD’s Top 10 Most Popular Stories for October 2020

OPTIMIZE: Svelte Direct Stenting Device Fails to Match DES

The PROSPECT ABSORB Trial: Randomized Evaluation of Vulnerable Plaque Treatment with Percutaneous Coronary Intervention

Prophylactic PCI of Vulnerable Plaques? PROSPECT II/ABSORB

Newer, Thinner-Strut Abbott Scaffold Prompts Talk of a BVS Comeback

Clopidogrel Interaction With Morphine in ACS Linked to More Ischemic Events

Ultrathin-Strut Orsiro Stent as Good as BioMatrix: BIODEGRADE

Impact of Calcified Plaque Angulation on Clinical Outcomes Following Bioresorbable Vascular Scaffold Implantation: Insights from ABSORB III and ABSORB Japan

The Post-Absorb BVS Era: Lessons Learned and Implications for Trial Design and Device Approval

The Absorb BVS Epilogue: How Did We Miss the Safety Signals?

TCT 7: Blinded Outcomes Assessment of Absorb Bioresorbable Scaffolds Implanted With Improved Technique: Two-year Results From the ABSORB IV Randomized Trial

ABSORB 5-Year Pooled Analysis: Improving Very Late Outcomes of the Absorb Bioresorbable Scaffold in Coronary Artery Disease From 4 Randomized Trials

Detection of Vulnerable Patients by NIRS (PROSPECT II) and Treatment (PROSPECT ABSORB) Rationale and Update

TCT 48: Bioresorbable Scaffold Versus Metallic Drug-Eluting Stent in Patients at High Risk of Restenosis (COMPARE-ABSORB trial) : Very late device thrombosis while on extended DAPT

TCT 47: Five-Year Clinical Outcomes From Randomized Comparison of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents in Patients With Coronary Artery Disease From ABSORB China Trial

TCT 11: Everolimus-eluting Bioresorbable Scaffolds versus Drug-eluting Stents in Patients with Acute Myocardial Infarction – 2-Year Results of the Randomized ISAR-Absorb MI Trial

SINOMED® Concludes Enrollment of the PIONEER III Randomized, Pivotal Study of the BuMA Supreme® Coronary Drug-Eluting Stent

Cardiogenic Shock Old and New: IABPs a Thing of the Past and ECMO Under Study

Daring to Dream: New BRS Data Hint at Low MACE Rates at 2 and 3 Years

Myocardial Blood Flow and Coronary Flow Reserve 3 Years After Absorb BVS vs DES: VANISH

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content